Clinical Trials

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06854003 2026-02-20

BRAZAN

Phase 2 Recruiting

60 enrolled

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Mantle-Cell

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, Follicular

NCT07206264 2025-10-03

ADAPT-MCL

45 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 2 Recruiting

20 enrolled

Phase 2 Active not recruiting

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

248 enrolled

CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT01415752 2025-04-08

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

373 enrolled 14 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT03615664 2025-01-16

BURGUND

115 enrolled

Phase 2 Not yet recruiting

Hodgkin Disease, Lymphoma

NCT06557330 2025-01-06

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

24 enrolled

Lymphoma

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

131 enrolled 28 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT01216683 2023-06-29

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

289 enrolled 34 charts

Lymphoma, Lymphoma, Follicular

NCT01412879 2021-10-29

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

53 enrolled 10 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT02499627 2021-05-27

FIL-BBV

Phase 2 Terminated

43 enrolled

Lymphatic Diseases, Lymphoma

NCT01490723 2020-05-05

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

20 enrolled 9 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00901927 2020-04-03

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase 2 Terminated

14 enrolled 10 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT03315520 2018-05-22

BeEAC-1

Phase 2 Unknown

100 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT01234467 2017-05-24

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

23 enrolled 16 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00705250 2017-03-03

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

36 enrolled 5 charts

Hodgkin Disease, Lymphoma

NCT01029730 2016-08-19

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

55 enrolled 7 charts

Lymphoma, Lymphoma, Non-Hodgkin

NCT00831597 2016-04-19

904

61 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00740415 2016-03-16

ManteauRiBVD

39 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT00069758 2014-05-09

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

72 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT01884441 2014-01-29

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Phase 2 Unknown

59 enrolled

Hodgkin Disease, Lymphoma, Recurrence

NCT01118845 2013-07-04

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

63 enrolled 46 charts

LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT01649622 2012-11-08

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Phase 2 Withdrawn

Leukemia, Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01131247 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Phase 2 Withdrawn

37 enrolled